newsfilter
← Latest News
Business Wire·

Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor